Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe
Key result
Real-world edoxaban shows low ~4% VTE recurrence and minimal major bleeding over 18 months.
- n=2,644
Why the study?
The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism in clinical practice are not well understood.
What are the real-world rates of recurrent VTE, major bleeding, and all-cause death in unselected patients with VTE treated with edoxaban for up to 18 months?
Population
2,644 unselected patients with VTE in eight European countries
Comparison
Edoxaban treatment for up to 18 months
Design
Prospective, noninterventional, post-authorization study
Follow-up
Up to 18 months
Authors
Discussion
Loading...
Member takes
Implication
Real-world edoxaban data may guide extended VTE therapy; leaves open optimal duration and risk stratification.
Study Design
Type
Observational (n=2,644)
Multicenter
Yes
Structured PICO
What are the real-world rates of recurrent VTE, major bleeding, and all-cause death in unselected patients with VTE treated with edoxaban for up to 18 months?
P
Population
2,644 unselected patients with venous thromboembolism treated with edoxaban in eight European countries, followed for up to 18 months.
E
Exposure
Edoxaban for up to 18 months (median treatment duration 50.6 weeks)
O
Outcome
Recurrent VTE, major bleeding, and all-cause deathhard clinical
Real-world data from ETNA-VTE Europe demonstrates that edoxaban treatment for up to 18 months in unselected VTE patients is associated with low rates of VTE recurrence, major bleeding, and all-cause death, aligning with clinical trial results.
Cite This Study
Agnelli et al. (2025) conducted an observational in Venous thromboembolism (VTE) (n=2,644). Edoxaban was evaluated on Recurrent VTE, major bleeding, and all-cause death. Real-world edoxaban treatment for up to 18 months in patients with VTE showed low rates of VTE recurrence (3.8%), major bleeding (1.4%), and all-cause death (3.6%).